Epigral growth over the years

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−0.9%+4.9%
EBITDA−20.2%−6.3%
Net Income−7.2%−2.1%
EPS (adj.)−7.2%−2.1%
Total Assets+11.2%+13.0%
Total Equity+16.7%+27.6%
Free Cash Flow−83.2%−41.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EPIGRAL₹907.30

Epigral Limited

· Chemicals
₹ CrorePeersYASHOGUJALKALIFCLFOSECOINDVISHNUTATVAGALAXYSURFJUBLCPLMcap ₹3,914 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-0.9+4.9
EBITDA-20.2-6.3
Net Income-7.2-2.1
EPS (adj.)-7.2-2.1
Total Assets+11.2+13.0
Total Equity+16.7+27.6
Free Cash Flow-83.2-41.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.